Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in two upcoming healthcare conferences. The company will attend Citi's Global Healthcare Conference in Miami on December 4, 2024, and Evercore's HealthCONx Conference in Coral Gables on December 5, 2024. Management will conduct one-on-one meetings at both events and participate in a fire-side chat at Evercore's conference at 12:55 ET. A live audio webcast of the fire-side chat will be available to investors through Alvotech's website, with the recording accessible for 90 days post-event.
Alvotech (NASDAQ: ALVO), un'azienda biotech globale focalizzata nello sviluppo di farmaci biosimilari, ha annunciato la sua partecipazione a due prossimi congressi sanitari. L'azienda parteciperà al Global Healthcare Conference di Citi a Miami il 4 dicembre 2024 e all'HealthCONx Conference di Evercore a Coral Gables il 5 dicembre 2024. La direzione condurrà incontri one-to-one in entrambi gli eventi e parteciperà a una chiacchierata informale al congresso di Evercore alle 12:55 ET. Un webcast audio live della chiacchierata sarà disponibile per gli investitori attraverso il sito web di Alvotech, con la registrazione accessibile per 90 giorni dopo l'evento.
Alvotech (NASDAQ: ALVO), una empresa biotecnológica global centrada en el desarrollo de medicamentos biosimilares, anunció su participación en dos próximas conferencias de salud. La empresa asistirá a la Global Healthcare Conference de Citi en Miami el 4 de diciembre de 2024, y a la HealthCONx Conference de Evercore en Coral Gables el 5 de diciembre de 2024. La dirección llevará a cabo reuniones uno a uno en ambos eventos y participará en un diálogo informal en la conferencia de Evercore a las 12:55 ET. Una transmisión en vivo del diálogo estará disponible para los inversores a través del sitio web de Alvotech, con la grabación accesible durante 90 días después del evento.
Alvotech (NASDAQ: ALVO)는 바이오시밀러 의약품 개발에 중점을 둔 글로벌 생명공학 회사로, 두 개의 다가오는 의료 회의에 참가할 것이라고 발표했습니다. 이 회사는 2024년 12월 4일 마이애미에서 열리는 Citi의 글로벌 헬스케어 컨퍼런스에 참석하고, 2024년 12월 5일 코럴게이블스에서 열리는 Evercore의 HealthCONx Conference에 참석할 것입니다. 경영진은 두 행사에서 일대일 미팅을 진행하며, Evercore의 회의에서 12:55 ET에 진행되는 대화에 참여합니다. 이 대화의 실시간 오디오 웹캐스트는 Alvotech의 웹사이트를 통해 투자자들에게 제공되며, 녹화된 내용은 이벤트 종료 후 90일간 접근할 수 있습니다.
Alvotech (NASDAQ: ALVO), une entreprise biopharmaceutique mondiale axée sur le développement de médicaments biosimilaires, a annoncé sa participation à deux prochaines conférences sur la santé. L'entreprise assistera à la Citi's Global Healthcare Conference à Miami le 4 décembre 2024 et à la HealthCONx Conference d'Evercore à Coral Gables le 5 décembre 2024. La direction mènera des réunions individuelles lors des deux événements et participera à une discussion informelle lors de la conférence d'Evercore à 12h55 ET. Un webinaire audio en direct de la discussion sera disponible pour les investisseurs via le site Web d'Alvotech, avec un enregistrement accessible pendant 90 jours après l'événement.
Alvotech (NASDAQ: ALVO), ein globales Biotech-Unternehmen, das sich auf die Entwicklung von biosimilaren Arzneimitteln spezialisiert hat, gab seine Teilnahme an zwei bevorstehenden Gesundheitskonferenzen bekannt. Das Unternehmen wird am Citi's Global Healthcare Conference in Miami am 4. Dezember 2024 und an der HealthCONx Conference von Evercore in Coral Gables am 5. Dezember 2024 teilnehmen. Das Management wird in beiden Veranstaltungen Einzelgespräche führen und an einem informellen Gespräch auf der Evercore-Konferenz um 12:55 ET teilnehmen. Ein Live-Audio-Webcast des Gesprächs wird den Investoren über die Website von Alvotech zur Verfügung stehen, wobei die Aufnahme 90 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi’s 2024 Global Healthcare Conference in Miami, Florida on December 4, 2024, and in Evercore’s HealthCONx Conference in Coral Gables, Florida on December 5, 2024. Members of the management team will host one-on-one meetings at both conferences. Alvotech will also hold a fire-side chat at Evercore’s HealthCONx Conference on Thursday, December 5, 2024 starting at 12:55 ET (17:55 GMT).
A live audio webcast of Alvotech’s fire-side chat at the Evercore HealthCONx Conference will be available to investors and the general public. Registration information for the audio webcast is available in the Investors Section of Alvotech’s website under News and Events – Events and Presentations. After the event, an audio recording of the event will be available for the next 90 days.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com.
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, X and YouTube.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
FAQ
When is Alvotech (ALVO) presenting at Evercore's HealthCONx Conference 2024?
Which healthcare conferences is Alvotech (ALVO) attending in December 2024?
How can investors access Alvotech's (ALVO) presentation at the Evercore HealthCONx Conference?
